Purpura: Clinical Trials

195 trials for Purpura, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

65 completed, 48 unknown, 37 recruiting, 15 terminated. 195 Phase 2, 28 Phase 1, 14 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 2195Completed 65, Unknown 48, Recruiting 37, Terminated 15, Not yet recruiting 14, Withdrawn 11, Active not recruiting 5
Phase 128Recruiting 11, Completed 7, Terminated 4, Not yet recruiting 3, Unknown 2, Withdrawn 1
Phase 314Completed 5, Unknown 4, Not yet recruiting 2, Recruiting 2, Withdrawn 1

Follow Purpura: new trials by email Literature Review of Purpura trials Research Report on Purpura

Trials (filtered) newest first · largest first

All 195 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Ianalumab in Addition to Eltrombopag in Pediatric Patients With Primary ITP Who Failed Corticosteroids.
Ianalumab, Eltrombopag - Primary Immune Thrombocytopenia (ITP)
Phase 2Not yet recruitingNovartis Pharmaceuticals362027-02-082026-06-25
An Open-label Phase I/II Safety and Feasibility Basket Study of UKT-CART19.1
CAR-T cells targeting CD19 - Pemphigus Vulgaris (PV), ANCA Associated Vasculitis (AAV)
Phase 1 / Phase 2Not yet recruitingUniversity Hospital Tuebingen362027-01-012026-11-12
A Phase 1b/2a Study of Velinotamig in Adults With Relapsed/Refractory ITP and wAIHA
Velinotamig specified dose on specified days. - Immune Thrombocytopenia (ITP), Warm Autoimmune Hemolytic Anemia (WAIHA)
Phase 1 / Phase 2Not yet recruitingCullinan Therapeutics Inc.722026-12-012026-07-31
Optimal Dose of Zanubrutinib to Treat Adult Immune Thrombocytopenia
Zanubrutinib 80mg/d, High dose dexamethasone, Zanubrutinib 160mg/d - Immune Thrombocytopenia
Phase 2Not yet recruitingPeking University People's Hospital902026-12-012026-11-12
TGD001 Treatment in Thrombotic Microangiopathies
TGD001 - Thrombotic Microangiopathies, ITP Immune-Mediated Thrombocytopenia
Phase 1 / Phase 2RecruitingTargED Biopharmaceuticals B.V.702026-10-252026-11-12
A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)
ianalumab, thrombopoietin receptor agonist (TPO-RA) - Primary Immune Thrombocytopenia (ITP), Primary Evans Syndrome (ES)
Phase 2RecruitingNovartis Pharmaceuticals1642026-08-042026-11-06
Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease
CTX112 - Warm Autoimmune Hemolytic Anemia (WAIHA), ITP - Immune Thrombocytopenia
Phase 1 / Phase 2RecruitingCRISPR Therapeutics AG602026-07-172026-10-20
Eltrombopag Plus Telitacicept vs. Eltrombopag Alone for Steroid-refractory/Relapsed ITP
Eltrombopag - Immune Thrombocytopenia
Phase 2Not yet recruitingInstitute of Hematology & Blood Diseases Hospital, China402026-07-102026-07-07
TPO-RA Plus Baricitinib vs. TPO-RA for ITP
Baricitinib, TPO-RA - ITP - Immune Thrombocytopenia
Phase 2Not yet recruitingPeking University People's Hospital1002026-07-012026-06-25
Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab
Ianalumab - Primary Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia
Phase 2WithdrawnNovartis Pharmaceuticals2026-06-262026-10-15
SG301-SC Injection Safety Study in Subjects With Primary ITP Patients
low dose group, high dose group, Placebo group - Primary Immune Thrombocytopenia
Phase 2RecruitingHangzhou Sumgen Biotech Co., Ltd.602026-06-112026-09-09
Sirolimus in Patients With Systemic Lupus Erythematosus-Associated Immune Thrombocytopenia
Sirolimus, Placebo - Systemic Lupus Erythematosus, Immune Thrombocytopenia
Phase 2 / Phase 3RecruitingChinese SLE Treatment And Research Group1642026-06-072026-06-18
Phase II Study of Orelabrutinib in Combination With Romiplostim N01 in Patients With Primary Immune Thrombocytopenia (ITP) Who Have Received At Least One Prior Line of Therapy
Orelabrutinib, Romiplostim N01 - Primary Immune Thrombocytopenia (ITP)
Phase 2Not yet recruitingPeking Union Medical College Hospital282026-04-012026-02-10
Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)
Rituximab, Daratumumab - Immune Thrombocytopenia, Treatment
Phase 2RecruitingInstitute of Hematology & Blood Diseases Hospital, China1222026-03-012026-01-23
Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
Rituximab combined with Daratumumab(Anti-CD38 Monoclonal Antibody) - Immune Thrombocytopenia, Treatment
Phase 2RecruitingInstitute of Hematology & Blood Diseases Hospital, China202026-03-012026-01-23
Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
Daratumumab(Anti-CD38 Monoclonal Antibody), Rituximab - Immune Thrombocytopenia, Treatment
Phase 2RecruitingInstitute of Hematology & Blood Diseases Hospital, China1602026-01-282026-02-11
Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
Rituximab, Daratumumab - Immune Thrombocytopenia, Treatment
Phase 2RecruitingInstitute of Hematology & Blood Diseases Hospital, China1602026-01-202026-02-11
A Study of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP) (TAI-SHAN11)
DZD8586 dose level 1, DZD8586 dose level 2, DZD8586 dose level 3 - Immune Thrombocytopenia (ITP)
Phase 2RecruitingDizal Pharmaceuticals602026-01-152026-01-22
Fecal Microbiota Transplantation for Steroid-resistant or Relapsed Immune Thrombocytopenia
Fecal microbiota transplantation - Immune Thrombocytopenia (ITP)
Phase 2Active not recruitingPeking University People's Hospital422026-01-102026-07-29
Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders
INCA000585 - Immune Thrombocytopenia
Phase 2RecruitingIncyte Corporation562025-12-292026-10-30

Showing 20 of 195. Sign in to see all of them.

Narrower conditions

Purpura, Thrombocytopenic, Idiopathic (168)  ·  Purpura, Thrombotic Thrombocytopenic (20)  ·  Thrombocytopenia (15)  ·  Purpura, Thrombocytopenic (9)  ·  Anemia, Hemolytic, Autoimmune (7)  ·  Evans Syndrome (5)  ·  Hematologic Diseases (5)  ·  IgA Vasculitis (5)  ·  Anemia, Hemolytic (4)  ·  Blood Platelet Disorders (4)  ·  Lupus Erythematosus, Systemic (4)  ·  Anemia (3)  ·  Arthritis, Rheumatoid (3)  ·  Autoimmune Diseases (3)

Broader conditions

Hemic and Lymphatic Diseases (195)  ·  Pathologic Processes (195)  ·  Pathological Conditions, Signs and Symptoms (195)  ·  Signs and Symptoms (195)  ·  Skin Manifestations (195)  ·  Blood Coagulation Disorders (194)  ·  Hemorrhage (194)  ·  Hematologic Diseases (190)  ·  Cytopenia (185)  ·  Thrombotic Microangiopathies (184)  ·  Blood Platelet Disorders (182)  ·  Immune System Diseases (177)  ·  Purpura, Thrombocytopenic (177)  ·  Hemorrhagic Disorders (173)

Interventions

Dexamethasone (25)  ·  Rituximab (23)  ·  eltrombopag (20)  ·  romiplostim (13)  ·  Danazol (12)  ·  avatrombopag (6)  ·  Immunoglobulins, Intravenous (5)  ·  daratumumab (5)  ·  zanubrutinib (5)  ·  Prednisone (4)  ·  Tretinoin (4)  ·  baricitinib (4)  ·  ianalumab (4)  ·  orelabrutinib (4)  ·  teriflunomide (4)

Sponsors

Peking University People's Hospital (39)  ·  Institute of Hematology & Blood Diseases Hospital, China (24)  ·  Shandong University (9)  ·  Novartis Pharmaceuticals (7)  ·  GlaxoSmithKline (5)  ·  Weill Medical College of Cornell University (5)  ·  Amgen (4)  ·  Assistance Publique - Hôpitaux de Paris (4)  ·  Hospital Universitario Dr. Jose E. Gonzalez (4)  ·  Archemix Corp. (2)  ·  Eisai Inc. (2)  ·  Hamilton Health Sciences Corporation (2)  ·  Keymed Biosciences Co.Ltd (2)  ·  Kyowa Kirin Co., Ltd. (2)  ·  National Heart, Lung, and Blood Institute (NHLBI) (2)

Countries

China (84)  ·  United States (54)  ·  United Kingdom (27)  ·  Spain (22)  ·  Germany (18)  ·  Italy (17)  ·  France (16)  ·  Poland (14)  ·  Australia (10)  ·  Canada (10)  ·  Austria (7)  ·  Greece (7)  ·  Czechia (6)  ·  Japan (6)  ·  Mexico (6)

Top investigators

Lei Zhang, MD (12)  ·  Xiao-Hui Zhang, MD (10)  ·  Xiaohui Zhang, MD (6)  ·  David Gomez-Almaguer, MD (3)  ·  James B Bussel, M.D. (3)  ·  Lei Zhang, M.D. (3)  ·  Ming Hou (3)  ·  Xiaohui Zhang (3)  ·  Jamie Y Hur, D.O. (2)  ·  Ming Hou, MD,PhD (2)

Results publications

PMID 24802773, PMID 23470153, PMID 24802775, PMID 36853224, PMID 12353309, PMID 15389904, PMID 17515510, PMID 18046028, PMID 18463354, PMID 19096013, PMID 19208097, PMID 19231632, PMID 19731307, PMID 19846889, PMID 20058208, PMID 20576011, PMID 20841509, PMID 21636861, PMID 22223819, PMID 22475545, PMID 22915649, PMID 23279219, PMID 23452139, PMID 23492914, PMID 23616916, PMID 23753021, PMID 23829485, PMID 25132654, PMID 25830126, PMID 26504182, PMID 26688484, PMID 26709028, PMID 26863353, PMID 27307776, PMID 27515248, PMID 27643485, PMID 27734464, PMID 28917657, PMID 29270980, PMID 29536526, PMID 30344993, PMID 30472651, PMID 30488420, PMID 30592022, PMID 30957581, PMID 31570488, PMID 31591739, PMID 31821591, PMID 32345372, PMID 33881463

NIH funding

2023 (5), 2018 (4), 2014 (2), 2019 (2), 2016 (1), 2025 (1), U10CA180888 (1), U54AR057319 (1), U54HL112303 (1)